2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10898
    GeX-2 2900996-95-2 98%
    GeX-2 is a truncated analogue of αO-conotoxin. GeX-2 activates GABAB receptor. GeX-2 inhibits α9α10 nAChR and CaV2.2 channels. GeX-2 alleviates pain in the rat model of chronic constriction injury.
    GeX-2
  • HY-P1090A
    Hemopressin(rat) TFA 1431329-47-3 98%
    Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models.
    Hemopressin(rat) TFA
  • HY-P1091A
    Hemopressin(human, mouse) TFA 1431329-48-4 98%
    Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models.
    Hemopressin(human, mouse) TFA
  • HY-P10932
    pGk13a 98%
    pGk13a is an amphipathic membrane-labeling probe containing an azide group, which can bind to fluorophores. pGk13a enables high-resolution imaging of cell membranes in the ultrastructure expansion microscopy (umExM) technique, facilitating the observation of membrane-associated structures and proteins. pGk13a is applicable to neuronal structure research.
    pGk13a
  • HY-P10936
    AQP4 (201-220) 2104700-59-4 98%
    AQP4 (201-220) is an encephalitogenic epitope of AQP-4. AQP4 (201-220) can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica.
    AQP4 (201-220)
  • HY-P10942
    CGN peptide 2421211-40-5 98%
    CGN peptide is a 13 amino acid peptide composed of D-amino acids, referred to as CGN peptide. CGN peptide is the retro-inverso isomer of the l-peptide TGN (TGNYKALHPHNG) and can deliver siRNA to the blood-brain barrier (BBB). CGN peptide can be used in Alzheimer's disease (AD) research.
    CGN peptide
  • HY-P10962
    Rugecitide 2938226-27-6 98%
    Rugecitide is a neuregulin 4 (NRG4) analog.
    Rugecitide
  • HY-P10972
    GIP (22-51) human 957470-49-4
    GIP (22-51) human (Glucose-dependent Insulinotropic Peptide (22-51) human) is a potent proatherosclerotic peptide hormone consisting of 30 amino acids. GIP (22-51) human can activate the NF-κB signaling pathway, promote the expression of MMP-8, and induce the expression of proinflammatory and proatherosclerotic proteins. GIP (22-51) human can also increase the level of intracellular free Ca2+ in THP-1-induced macrophages. GIP (22-51) human can be used in the research of atherosclerosis.
    GIP (22-51) human
  • HY-P10977
    Tat-ASIC1a (1-20) (mouse, rat) 98%
    Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the ASIC1a-RIPK1 pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease.
    Tat-ASIC1a (1-20) (mouse, rat)
  • HY-P10979
    Buccalin 116786-35-7
    Buccalin is a neuropeptide that colocalizes with small molecule cardioactive peptides in neuronal B15. When exogenously applied to the ARC neuromuscular junction, Buccalin reduces the amplitude of muscle contraction induced by motor neuron firing and acts only presynaptically. Buccalin has no effect on the rate of muscle relaxation and reduces motor neuron-induced ARC excitatory junction potentials without affecting contraction produced by direct acetylcholine action on the muscle.
    Buccalin
  • HY-P11045
    JNJ63955918
    JNJ63955918 is a potent, highly selective, blocked-state Nav1.7 blocking peptide with an IC50 of 8.0 nM. JNJ63955918 can be used in pain research.
    JNJ63955918
  • HY-P11047
    QSH peptide 470459-60-0
    QSH peptide is a peptide that specifically binds to Aβ1-42 and is used in the synthesis of siRNA delivery complexes. QSH peptide can be used in Alzheimer's disease (AD) research.
    QSH peptide
  • HY-P11048
    Thrombin-cleavable peptide 2412575-90-5
    Thrombin-cleavable peptide is a type of peptide that can be recognized and cleaved by thrombin. After cleavage, Thrombin-cleavable peptide releases thrombolytic peptides to initiate thrombolysis. Thrombin-cleavable peptide can be used in the research of diseases such as ischemic stroke.
    Thrombin-cleavable peptide
  • HY-P11049
    Stroke-homing peptide
    Stroke-homing peptide is a homing peptide. Stroke-homing peptide can home to ischemic stroke brain tissue and detect the apoptotic neuronal cells. Stroke-homing peptide can be used for the research of molecular imaging and selective drug delivery to stroke tissue.
    Stroke-homing peptide
  • HY-P11082
    APGW-amide 126675-52-3 98%
    APGW-amide is a neuropeptide. APGW-amide controls the growth of imposex structures and promotes growth in Haliotis asinina. APGW-amide inhibits Achatina neurons and modulates neuronal currents induced by neuroactive compounds. APGW-amide induces a rapid increase in [Ca2+]i in Fura-2/AM-loaded PC12 cells. APGW-amide is useful for research on the nervous system.
    APGW-amide
  • HY-P11092
    TLQP-62 (mouse,rat)
    TLQP-62 (mouse,rat) is a secreted C-terminal peptide that can be derived from protein VGF. TLQP-62 activates the BDNF-TrkB signaling pathway, inducing acute, transient phosphorylation of TrkB receptor and downstream CREB (Ser133) phosphorylation. TLQP-62 demonstrates excellent efficacy in promoting long-term fear memory formationin wild-type mice and reversing memory impairment in VGF heterozygous knock-out mice. TLQP-62 can be used for the study of memory-related neurological disorders (e.g., Alzheimer’s disease, frontotemporal dementia).
    TLQP-62 (mouse,rat)
  • HY-P11105
    Short neuropeptide F 1202582-76-0
    Short neuropeptide F is an insect neurohormone involved in regulating insect locomotor activity and circadian rhythm.
    Short neuropeptide F
  • HY-P11119
    CKS peptide 98%
    CKS peptide is a selective substrate peptide for CK1. CKS peptide can used to measure CK1 activity.
    CKS peptide
  • HY-P11124
    MGF24 1611488-66-4
    MGF24 is a modified protease-resistant MGF derivative. MGF24 protects dopaminergic neurons from 6-Hydroxydopamine (6-OHDA) (HY-113028)-induced apoptosis by inducing Heme oxygenase-1 (HO-1). MGF24 activates PKC-ε, which in turn activates Nrf2, up-regulating HO-1. MGF24 has neuroprotective activity and reduces myocardial infarct size in sheep models of myocardial ischemia. MGF24 can be used for neurological diseases like stroke, nerve injury and amyotrophic lateral sclerosis research.
    MGF24
  • HY-P1112A
    Sarafotoxin S6a TFA 98%
    Sarafotoxin S6a TFA , a sarafotoxin analogue, is a endothelin receptor agonist and has an ETA/ETB selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a TFA elicits the pig coronary artery with an EC50 value of 7.5 nM.
    Sarafotoxin S6a TFA
Cat. No. Product Name / Synonyms Application Reactivity